The socio‐economic burden of H1‐antihistamine‐refractory chronic spontaneous urticaria in Germany

Author:

Augustin Matthias1ORCID,Beier Dominik2,Branner Jennifer3,Häckl Dennis4,Hampel Regina5,Kramps Thomas6,Kurzen Hjalmar7,Lintener Hannah3,Melzer Nima6,Müller Malina3,Staubach Petra8,Schwichtenberg Uwe9,Termeer Christian1011,Zink Alexander1213ORCID,Nathan Petra6ORCID,Maurer Marcus1415ORCID

Affiliation:

1. Universitätsklinikum Hamburg Eppendorf, IVDP Hamburg Germany

2. InGef—Institut für angewandte Gesundheitsforschung Berlin Berlin Germany

3. WifOR Institute Darmstadt Darmstadt Germany

4. WIG2 Wissenschaftliches Institut für Gesundheitsökonomie und Gesundheitssystemforschung Leipzig Leipzig Germany

5. GKM Therapieforschung München München Germany

6. Novartis Pharma GmbH Nürnberg Germany

7. Haut‐und Laserzentrum Freising Freising Germany

8. Department of Dermatology University Medical Center Mainz Mainz Germany

9. Derma‐Nord Hautarztpraxis Bremen Bremen Germany

10. Practice Stuttgart Germany

11. Department of Dermatology University of Freiburg Freiburg Germany

12. Klinik und Poliklinik für Dermatologie und Allergologie am Biederstein, Fakultät für Medizin Technische Universität München Munich Germany

13. Division of Dermatology and Venereology, Department of Medicine Solna Karolinska Institutet Stockholm Sweden

14. Institute of Allergology, Charité—Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin and Humboldt‐Universität zu Berlin Berlin Germany

15. Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology Berlin Germany

Abstract

AbstractBackground and Study AimData from the AWARE study (A Worldwide Antihistamine‐Refractory chronic urticaria patient Evaluation) illustrate a substantial disease burden in German patients with H1‐antihistamine (‐H1‐AH)‐refractory chronic spontaneous urticaria (CSU). Detrimental effects on patients' quality of life, poor disease control and impairment in the ability to work and perform other daily activities are reported. Based on these findings, this study aims to quantify the epidemiological and socio‐economic burden of H1‐AH‐refractory CSU in Germany.MethodsTo determine the epidemiological burden of H1‐AH‐refractory CSU, the age‐ and gender‐specific prevalence of CSU and the proportion of H1‐AH‐refractory patients in Germany anonymized data from the InGef research database have been used. In a second step, the socio‐economic burden in terms of lost numbers of hours in paid and unpaid work was calculated by extrapolating the age‐ and gender‐specific work productivity and activity impairment (WPAI) observed in AWARE to the H1‐AH‐refractory CSU population in Germany. Finally, productivity losses in paid and unpaid work were monetized using the human capital and the friction cost approach respectively. Moreover, socio‐economic burden was calculated depending on symptom control of the patients (measured by urticaria control test [UCT]).ResultsIn Germany, over 203,000 patients (20 years or older) had H1‐AH‐refractory CSU in 2018. The avoided lost paid and unpaid work hours attributable to H1‐AH‐refractory CSU summed up to over 100 million. Overall, the socio‐economic burden of H1‐AH‐refractory CSU in monetary terms was evaluated at € 2.2 billion and the majority of this was due to unpaid work loss. Patients with poor disease control, as indicated by UCT score < 12, were more likely to suffer from high impairment than patients with controlled disease, resulting in a higher socio‐economic burden.ConclusionThe results of our analyses picture the substantial socio‐economic burden of H1‐AH‐refractory CSU and therefore the tremendous impact it has on daily lives of individuals and society overall.

Funder

Novartis Pharma

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3